Kemp Dolliver

Stock Analyst at Brookline Capital

(0.67)
# 4,104
Out of 5,126 analysts
19
Total ratings
38.46%
Success rate
-11.96%
Average return

Stocks Rated by Kemp Dolliver

Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $4.54
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $6.91
Upside: +146.02%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.97
Upside: +262.17%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.42
Upside: +48.76%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $1.69
Upside: +2,030.18%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.43
Upside: +7,212.53%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $64.89
Upside: +54.11%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.12
Upside: +4,989.29%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.39
Upside: +946.03%
Initiates: Buy
Price Target: $19
Current: $5.45
Upside: +244.04%
Assumes: Buy
Price Target: $8
Current: $0.77
Upside: +940.45%
Initiates: Buy
Price Target: $5.65
Current: $0.59
Upside: +857.63%